PDCD1 and neoplasm: Also, to overcome an immunosuppressive TME, several studies suggested that the combination of monoclonal antibodies inhibiting immune checkpoints such as PD-1 or CTLA-4 and CAR-T cell therapy might result in improved anti-tumor activity (128, 129).